Compulsory Acquisition of Outstanding Minster Pharmaceuticals plc Shares

On 4 January 2010, the boards of Proximagen Neuroscience plc ("Proximagen") and Minster Pharmaceuticals plc ("Minster") announced the recommended offer by Proximagen for the entire issued and to be issued share capital of Minster (the "Offer").

Board Changes, Issue of Deferred Consideration Shares and Cancellation of Listing

Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, announces that further to the announcement made earlier today confirming that the recommended cash offer by Proximagen Neuroscience Plc for the entire issued share capital of the Company (the "Offer") has now been declared unconditional in all respects, Kenneth Mulvany and James Hunter have been appointed to the board of directors.

Posting of Offer Document

On 4 January 2010, the boards of Proximagen Neuroscience plc ("Proximagen") and Minster Pharmaceuticals plc ("Minster") announced the recommended offer by Proximagen for the entire issued and to be issued share capital of Minster (the "Offer"). Proximagen announces that an offer document (“Offer Document”) and a form of acceptance containing the final terms and conditions of the Offer, will today be posted to eligible Minster Shareholders.

RECOMMENDED CASH OFFER

The Boards of Proximagen and Minster are pleased to announce that they have today reached agreement on the terms of a recommended cash offer by Proximagen for the entire issued and to be issued share capital of Minster.
Under the terms of the Offer, Minster Shareholders will receive 6.0 pence in cash for each Minster Share held by them, valuing the entire issued and to be issued share capital of Minster at approximately £4.3 million.

Interim Results for the six months ended 30 September 2009

Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, is pleased to announce its results for the six months ended 30 September 2009.

Mr Robert Aubrey steps down from executive responsibilities

Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, announces that Robert Aubrey, an Executive Director, will step down from executive responsibilities with effect from 30 September 2009 to become a Non-executive Director.

Change of Registered Office

Minster Pharmaceuticals plc (AIM: MPM) announces that its registered office has been changed to Salisbury House, Station Road, Cambridge, Cambridgeshire, CB1 2LA, with immediate effect.

Tonabersat featured at International Headache Society Congress

Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, is pleased to announce that tonabersat, the Company’s novel compound with potential in a number of neurological conditions, was featured at the 14th Congress of the International Headache Society (IHS), which was held in Philadelphia, Pennsylvania, on 10-13th September 2009.